Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 13,669 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the completion of the transaction, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

David Moatazedi also recently made the following trade(s):

• On Tuesday, March 17th, David Moatazedi sold 116,720 shares of Evolus stock. The shares were sold at an average price of $4.89, for a total transaction of $570,760.80.
• On Monday, December 22nd, David Moatazedi sold 10,539 shares of Evolus stock. The stock was sold at an average price of $7.15, for a total value of $75,353.85.

Evolus Price Performance

NASDAQ:EOLS opened at $4.64 on Friday. Evolus, Inc. has a 1 year low of $4.09 and a 1 year high of $13.30. The stock’s fifty day moving average price is $4.79 and its two-hundred day moving average price is $6.05. The company has a market cap of $301.88 million, a P/E ratio of -5.73 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. On average, analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EOLS. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Mizuho set a $15.00 price objective on shares of Evolus in a research note on Wednesday, February 4th. BTIG Research reaffirmed a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Stifel Nicolaus cut their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Institutional Trading of Evolus

Institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP purchased a new position in shares of Evolus during the fourth quarter worth about $545,000. Alpine Global Management LLC bought a new stake in Evolus during the fourth quarter valued at approximately $173,000. Virtu Financial LLC bought a new stake in Evolus during the fourth quarter valued at approximately $151,000. Mercer Global Advisors Inc. ADV purchased a new position in Evolus in the 4th quarter worth approximately $144,000. Finally, Wellington Management Group LLP grew its stake in Evolus by 5.9% in the 4th quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock worth $1,298,000 after buying an additional 10,850 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.